Balance Sheet
Cash Flow Statement
AmortizationAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Net Cash Flow (2019 - 2025)

Historic Net Cash Flow for Legend Biotech (LEGN) over the last 7 years, with Q3 2025 value amounting to $9.5 million.

  • Legend Biotech's Net Cash Flow fell 9632.23% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$220.8 million, marking a year-over-year increase of 5634.88%. This contributed to the annual value of -$1.0 billion for FY2024, which is 32996.19% down from last year.
  • According to the latest figures from Q3 2025, Legend Biotech's Net Cash Flow is $9.5 million, which was down 9632.23% from -$179.6 million recorded in Q2 2025.
  • In the past 5 years, Legend Biotech's Net Cash Flow ranged from a high of $570.8 million in Q2 2023 and a low of -$696.3 million during Q2 2024
  • Its 5-year average for Net Cash Flow is -$33.5 million, with a median of -$43.7 million in 2021.
  • As far as peak fluctuations go, Legend Biotech's Net Cash Flow plummeted by 61155.27% in 2022, and later surged by 1989989.49% in 2023.
  • Over the past 5 years, Legend Biotech's Net Cash Flow (Quarter) stood at -$69.9 million in 2021, then surged by 63.38% to -$25.6 million in 2022, then soared by 1322.17% to $312.8 million in 2023, then plummeted by 165.31% to -$204.3 million in 2024, then skyrocketed by 104.64% to $9.5 million in 2025.
  • Its Net Cash Flow stands at $9.5 million for Q3 2025, versus -$179.6 million for Q2 2025 and $153.6 million for Q1 2025.